Conatus Pharmaceuticals Receives $20,000,000 Series B Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=144d2fa4-c980-4e08-b792-d3edced8bd62&Preview=1 -
Date
2/13/2011 -
Company Name
Conatus Pharmaceuticals -
Mailing Address
4365 Executive Drive San Diego, CA 92121 -
Company Description
The Conatus team pioneered the science of apoptosis and the clinical development of pan caspase inhibitors, validating this first-in-class technology. Conatus has well established relationships with key opinion leaders in the fields of hepatology, infectious disease and inflammation. -
Website
http://www.conatuspharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$20,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate the Company has licensed from F. Hoffman-La Roche, Ltd. and is the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients. -
M&A Terms
-
Venture Investor
AgeChem Venture Fund -
Venture Investor
Aberdare Ventures -
Venture Investor
Advent Venture Partners -
Venture Investor
Bay City Capital -
Venture Investor
Glide Healthcare Partners -
Venture Investor
Roche Venture Fund
